Literature DB >> 1538152

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

G R Siber1, J Leszcynski, V Pena-Cruz, C Ferren-Gardner, R Anderson, V G Hemming, E E Walsh, J Burns, K McIntosh, R Gonin.   

Abstract

To explore the feasibility of preparing a human immune globulin specific for respiratory syncytial virus (RSV) by screening plasma donors, the ability of seven RSV antibody assays to identify plasma-yielding IgG with high virus-neutralizing and animal-protective activities was compared. IgG prepared from plasma units selected by microneutralization assay had significantly higher activity in protecting mice from respiratory RSV challenge than did IgGs prepared from plasmas selected by three direct ELISAs using purified F protein, G protein, or RSV-infected cell lysate, by two competitive ELISAs with RSV neutralizing monoclonal antibodies directed to the F2 or F3 epitopes of the F protein, or by plaque reduction neutralization. Relative to IgG made from unselected plasma, microneutralization-screened IgG was enriched fivefold by plaque-reduction neutralization assays done with or without complement. The microneutralization assay identified RSV antibodies with highest animal protective activity. This assay will be useful for identifying plasma donors for the preparation of a human immune globulin with high protective activity against RSV and deserves further evaluation for prediction of protective antibody concentrations in children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538152     DOI: 10.1093/infdis/165.3.456

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Authors:  H C Meissner; J R Groothuis; W J Rodriguez; R C Welliver; G Hogg; P H Gray; R Loh; E A Simoes; P Sly; A K Miller; A I Nichols; D K Jorkasky; D E Everitt; K A Thompson
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Respiratory syncytial virus immune globulin intravenous.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-01       Impact factor: 2.253

3.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

4.  Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

Authors:  R D LeClaire; S Bavari
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 5.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 6.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

8.  Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.

Authors:  R Weltzin; S A Hsu; E S Mittler; K Georgakopoulos; T P Monath
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Raymonde O Oue; Mira C Patel; Marina S Boukhvalova
Journal:  Vaccine       Date:  2015-08-31       Impact factor: 3.641

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.